Pharmaceutical

Oncolytics targets accelerated approval for oncolytic virus therapy

The company intends to start a registrational Phase II trial of pelareorep and chemotherapy combination for breast cancer in 2025.

Oct 8, 2024 - 04:00
Oncolytics targets accelerated approval for oncolytic virus therapy
The company intends to start a registrational Phase II trial of pelareorep and chemotherapy combination for breast cancer in 2025.
Read the original article

Tags:

Previous Article

EMA starts review into hair loss drugs about potential link to suicidal thoughts 

Next Article

Activist investor Starboard forges $1bn stake in Pfizer to swing profits

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Coeptis licenses Deverra Therapeutics’ clinical stage assets

Coeptis licenses Deverra Therapeutics’ clinical stage a...

Aug 18, 2023

STAT+: Narcan manufacturer aims to price over-the-counter kit under $50

STAT+: Narcan manufacturer aims to price over-the-count...

Apr 21, 2023

Janssen seeks EMA approval of RYBREVANT for NSCLC

Janssen seeks EMA approval of RYBREVANT for NSCLC

Feb 10, 2024